DengiAll Vaccine

About DengiAll Vaccine

• DengiAll: It is India’s indigenous tetravalent dengue vaccine designed to protect against all four dengue virus serotypes.
• Developed by: DengiAll has been developed by Panacea Biotec in collaboration with the Indian Council of Medical Research (ICMR).
• Vaccine Type: DengiAll is a live-attenuated tetravalent dengue vaccine that combines weakened forms of DENV-1, DENV-2, DENV-3, and DENV-4.
  • Live-Attenuated Vaccines: These vaccines contain weakened forms of pathogens that can trigger a strong and long-lasting immune response without causing illness in healthy individuals.
• Current Status: The Phase 3 clinical trial of DengiAll was conducted in 2024 with more than 10,335 participants across 19 sites in 18 States and Union Territories.
• Dosing: DengiAll is a two-dose vaccine followed by two years of medical follow-up.
• Efficiency: Early Phase 1 and Phase 2 clinical trials demonstrated an efficacy rate of 77% to 82% and showed a balanced antibody response against all four dengue virus serotypes, indicating promising protection against dengue infection.
• NIH-Based Technology: It is derived from the TV003/TV005 strain originally developed by the U.S. National Institutes of Health (NIH).

About Dengue

• Nature of Disease: Dengue, also known as break-bone fever, is a mosquito-borne viral infection.
• Occurrence: It is more common in tropical and subtropical regions, especially in urban and semi-urban areas.
• Transmission: The disease spreads through the bite of infected Aedes mosquitoes carrying one of the four dengue virus serotypes.
• Serotypes: The dengue virus has four serotypes—DENV-1, DENV-2, DENV-3, and DENV-4—and all four serotypes are known to circulate in India.
• Symptoms: Common symptoms include high fever, headache, body aches, nausea, and rash, while severe cases may cause bleeding and breathing difficulties.
• Treatment: There is no specific medicine for dengue, and treatment mainly involves pain relief, rest, and adequate fluid intake.